Danaher Reports Fourth Quarter and Full Year 2024 Results

WASHINGTON, Jan. 29, 2025 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the fourth quarter and full year 2024.  All results in this release reflect only continuing operations unless otherwise noted. Key Fourth Quarter 2024 Results Net earnings were $1.1 billion, or $1.49 per diluted common share and non-GAAP adjusted diluted... Read more

Change to the Roche Enlarged Corporate Executive Committee

Basel, 29 January 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Wafaa Mamilli (1967) will join the company as Chief Digital Technology Officer (CDTO), reporting to Group CEO, Thomas Schinecker, and will become a member of the enlarged Corporate Executive Committee starting 10 February 2025.  She will be based at Genentech in South... Read more

Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer

Updated overall survival (OS) results – a key secondary endpoint – reinforce the significant benefit of the ItovebiTM (inavolisib)-based regimen for patients with advanced PIK3CA-mutated, HR-positive, HER2-negative breast cancer in the first-line setting Primary analysis showed the Itovebi-based regimen reached statistical significance, more than doubling progression-free survival in this patient population1 Full OS results from... Read more

Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)

Across three key functional outcomes, North Star Ambulatory Assessment (NSAA), Time to Rise (TTR) and 10-meter walk/run (10MWR), results were statistically significant and clinically meaningful two years after treatment with Elevidys, compared to a pre-specified propensity-weighted untreated external control group Functional differences between individuals treated with Elevidys and those in the external control group increased... Read more

MKS Instruments Completes Repricing on its Secured Term Loan B USD and EUR Tranches and Makes a $100 Million Voluntary Prepayment on its Secured Term Loan B USD

ANDOVER, Mass. , Jan. 24, 2025 (GLOBE NEWSWIRE) — MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, announced today that it successfully completed the repricing of its $2.5 billion and €0.6 billion secured tranche B term loans maturing in Read more

PacBio Names Global Institute for Food Security as Canada's First Revio Certified Service Provider

MENLO PARK, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the Global Institute for Food Security (GIFS) at the University of Saskatchewan (USask) as the first Revio PacBio Certified Service Provider (CSP) in Canada. Known for its leadership in animal, microbial and plant... Read more

Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care

More than 1 million curable sexually transmitted infections (STIs) are acquired every day worldwide in people 15–49 years old, most of which are asymptomatic.1 FDA CLIA-waived tests broaden access to accurate, easy-to-use diagnostics for all patients in decentralized settings like urgent care centers, retail clinics, and community health venues. The tests use highly sensitive, gold-standard... Read more

JEOL USA Introduces New Broad Ion Beam Milling, Cross Section Polisher™

January 20, 2025, Peabody, MA.  JEOL USA announces the release of its new broad ion beam milling instruments, Cross Section Polisher™ (CP) and Cooling Cross Section Polisher™ (CCP).  These instruments are widely used for preparing high quality, artifact-free cross sections for imaging and microanalysis by SEM, EPMA or Auger. These new configurations have an improved... Read more